Hot

重组人IgG4-S228P同型对照抗体 | Syd Labs PA007128

重组人IgG4-S228P同型对照抗体 Syd Labs PA007128 - 武汉多找找科技

重组人IgG4-S228P同型对照抗体 | Syd Labs PA007128

In stock

一键复制

Syd Labs 体内实验级重组人IgG4-S228P同型对照抗体(货号:PA007128)是用CHO细胞生产的重组抗体,人源化可变区和人IgG4 kappa不变区,适用于体内和体外研究。高性价比的重组人IgG4 kappa同型对照突变体,hIgG4 S228P和SPLEPG,可提供嵌合版本和优质级(内毒素≤0.05 EU/mg),与经测试的人体样本的特异性结合程度低或无特异性结合。

SKU: PA007128 分类: ,

产品参数

货号 PA007128
产品名称重组人IgG4-S228P同型对照抗体 | Syd Labs PA007128
英文名 In Vivo Grade Recombinant Human IgG4-S228P Isotype Control Antibody
供货商名称 Syd Labs, Inc.
品牌名 Syd Labs
别称 hIgG4同型对照抗体,人IgG4同型对照抗体,hIgG4 S228P, hIgG4 SPLEPG突变体
概述 Syd Labs 体内实验级重组人IgG4-S228P同型对照抗体用CHO细胞生产的重组抗体,适用于体内和体外研究。
克隆号 1R12
同种型 人 IgG4, kappa
应用 用于ELISA、Western Blot (WB)、流式细胞术(Flow)、免疫沉淀(IP)、免疫组织化学(石蜡)(IHC (P))、免疫组织化学(Frozen) (IHC (F))和体内动物模型研究的人IgG4 kappa抗体的同型匹配阴性对照。
免疫源 Trinitrophenol (TNP)
抗体形式 0.2 μM过滤溶液,1x PBS
内毒素 根据 LAL 方法,≤ 1 EU每 1 mg 蛋白质。提供特级体内实验级重组人IgG4-S228P同型对照抗体(内毒素≤0.05 EU/mg)。
纯度 >95%(在还原条件下通过SDS-PAGE测定)
运输 体内实验级重组人IgG4-S228P同型对照抗体用冰袋运输。收到后,请立即将其存放在下面建议的温度下。
稳定性与存储 使用手动除霜冰箱并避免重复冻融循环。 如果保存在2 至 8°C,自收到之日起可保存3个月。如果保存在-20 至 -70°C,自收到之日起可保存 12个月。
注意事项 PA007128 Syd Labs:重组人IgG4 κappa同型对照突变体hIgG4 S228P和SPLEPG适用于体内和体外研究,可提供嵌合版本和优质级(内毒素≤0.05 EU/mg),与经测试的人体样本的特异性结合程度低或无特异性结合。人源化可变区和人IgG4 kappa不变区。
产品咨询 Syd Labs在国内只通过代理商销售其产品,不做直销。终端用户咨询价格请联系Syd Labs中国代理商。
关于Syd Labs产品如果有任何技术或其它问题,欢迎随时联系Syd Labs国内市场推广合作伙伴:武汉多找找科技有限公司,企业微信:duozhaozhao2024 联系电话:18162581039(龙经理)
应用详情 用于ELISA、Western Blot (WB)、流式细胞术(Flow)、免疫沉淀(IP)、免疫组织化学(石蜡)(IHC (P))、免疫组织化学(Frozen) (IHC (F))和体内动物模型研究的人IgG4 kappa抗体的同型匹配阴性对照。

文献

PA007128:重组人IgG4-S228P同型对照抗体,体内实验级(In Vivo Grade Recombinant Human IgG4-S228P Isotype Control Antibody)

理想的重组人IgG4同型对照抗体(hIgG4 S228P kappa同型对照)对任何人类样本均无特异性结合或仅有极低结合,其拥有人源化或完全人源的重链可变区,以及人IgG4 S228P kappa恒定区。在评估全人源、人源化或嵌合抗体时,该人IgG4 kappa同型对照及其突变体可用作细胞实验或动物模型中的抗体阴性对照。

开发hIgG4同型对照突变体是为了匹配某些人IgG4治疗性抗体候选药物中所引入的相应突变。例如,核心铰链区中引入的S228P工程化突变可用于防止人IgG4分子在体内的Fab臂交换;而P329G突变与S228P和L235E组合使用,已被证明可通过破坏Fc与Fcγ受体界面来降低效应功能。当客户评估其工程化改造的抗体候选物时,具有静默Fc效应功能的人IgG4同型对照对于体内实验非常有用。

欢迎联系我们并获取工程化人IgG4同型对照突变体、带有Avi、His和DYKDDDDK标签的hIgG4同型对照及Fc静默突变体,以及生物素化hIgG4同型对照和Fc静默突变体的报价。此外,我们还提供人IgG4同型对照及Fc静默效应突变体的多种偶联物(如染料和荧光团)。

人IgG4-S228P同型对照抗体部分参考文献:

1.Enhanced IL-15-mediated NK cell activation and proliferation by an ADAM17 function-blocking antibody involves CD16A, CD137, and accessory cells
Anders W Matson, et al. J Immunother Cancer. 2024;12(7):e009187. PMCID: PMC11284835
“The anti-human ADAM17 mAb MEDI3622 has been previously described. The following Fc variants were generated from its nucleotide sequence. Human isotypes IgG1 and IgG4 were generated by Syd Labs (Natick, Massachusetts, USA) and are referred to as Medi-1 and Medi-4, respectively. The mutations Pro329Gly, Leu234Ala, and Leu235Ala (PGLALA) were engineered into the Fc region of Medi-1 (Syd Labs) to impair FcγR binding and is referred to as Medi-PGLALA. The Fc region of Medi-1 was proteolytically removed …… and is referred to Medi-F(ab′)2. The Trispecific Killer Engager (TriKE) containing a human IL-15 moiety and humanized camelid single-domain antibodies against CD16A and B7H3 (cam16-IL15-camB7H3), as well as a Targeted ADAM17 Blocker-16 (TAB16), containing a single-chain fragment variable (scFv) from Medi-1 and a humanized camelid single-domain antibody against CD16, were generated similar to as previously described. All commercially available antibodies are listed in table 1. Any antibodies used in functional assays that contained a preservative, such as sodium azide (NaN3), were subjected to a Zeba Spin Desalting Column 40K …… according to the manufacturer’s instructions, and resuspended in PBS buffer without Ca+2 and Mg+2 …… ”

2.Discovery and characterization of prolactin neutralizing monoclonal antibodies for the treatment of female-prevalent pain disorders
Stephanie Maciuba, et al. MAbs. 2023;15(1):2249814. PMCID: PMC10498814
“FcγR binding of PRL mAbs or human IgG1 (Syd Labs Inc., #PA007125), IgG2 (Syd Labs Inc., #PA007127), and IgG4(S228P) (Syd Labs Inc., #PA007128) isotype controls were estimated using NanoBiT FcγR binding immunoassays …… as described previously. Briefly, serial dilutions of each antibody were co-incubated with recombinant, biotin-labeled FcγRs (FcγRI, FcγRIIAH131, FcγRIIAR131, FcγRIIIAF158, FcγRIIIAV158) tagged with streptavidin-SmBiT partial luciferase enzyme in the presence of tracer IgG conjugated to the LgBiT partial luciferase enzyme for 30 minutes at room temperature in wells of white 384-well plates. In the absence of exogenous antibody competition, the interaction between the IgG-LgBiT and SmBiT-labeled FcγR facilitates the formation of a functional NanoBiT luciferase enzyme. After incubation, furimazine luciferase substrate …… was added to each well, and the bioluminescence signal (RLU) was measured after stabilizing for 3 minutes using a TECAN SPARK multimode plate reader. RLU data was normalized by assigning the maximum RLU in the absence of competing antibody as 100%, and the percentage decrease in signal in the presence of test antibody was calculated. The IC50 of each antibody for each FcγR immunoassay was estimated using the four-parameter logistic regression analysis of GraphPad Prism v9.4.1 …… ”

3. DEspRhigh neutrophils are associated with critical illness in COVID-19
deKay, J. T., et al. Sci Rep. 2021 Nov 17;11(1):22463. doi: 10.1038/s41598-021-01943-7. PMID: 34789851; PMCID: PMC8599677
“Subpopulations of WBC were analyzed using the following antibodies: CD3 (UCHT1), CD4 (OKT4), CD8a (HIT8a), CD10 (HI10a), CD14 (HCD14), CD16 (3G8), CD26 (BA5b), CD38 (HIT2), CD45 (HI30), CD73 (AD2), HLA-DR (LN2430) …… Human anti-human/mouse DEspR antibody (NCTX-01) was provided by NControl Therapeutics …… Human IgG4-S228P isotype control was obtained from Syd Labs (Southborough, MA). Both anti-DEspR and isotype IgGs were conjugated with Alexa Fluor 647 using Molecular Probes® Alexa Fluor® Antibody Labeling Kits …… Subpopulations of cells were defined as follows: side scatter (SSC)high/CD16high/CD14low/−/HLA-DR negative neutrophils, SSCintermediate/CD14high/HLA-DR positive monocytes, SSClow/CD14negative lymphocytes. Subsets of CD4 and CD8 T cells coexpressing CD73 and CD26 were determined within the subpopulation of CD3 positive cells.”